合作类型：技术     行业类别: 诊断       过期时间：2016年10月24日   

法国癌症中心已鉴别出了一种新的蛋白质生物标记物，主要针对乳腺癌和结肠癌。该新的生物标记物可较为准确的诊断和预测这两种癌症。目前正在寻找许可证协议和技术合作。

英文原文：A french cancer center has identified a new protein biomarker, highly specific for breast and colon cancer. This new biomarker allows for a more accurate diagnostic and prognostic for both illness. Industrial partners are sought for licence agreement or technical cooperation. The use of prognosis biomarkers is verry important in helping clinicians in their therapeutic decision. First generation biomarkers currently in use for diagnosis / prognosis of breast and colon cancer often lead to false-positive results. New generation biomarkers currently under development will help with clearer and accurate prognosis. The laboratory has identified a new protein biomarker, highly specific for breast and colon cancer, which more accurately helps predicts the risk for cancer to relapse and/or to develop metastases. The analysis of this marker expression by TMA (Tissue MicroArrays) immunohistochemistry on breast and colon cancer samples, has demonstrated that colorectal tumors showing more than 50% positively-stained cells or breast tumors showing less than 50% positively-stained cells are related to high risks of relapse, either local or metastatic. Partners for technical cooperation agreement are sought in order to improve the biomarker results. The addition of a single protein marker to predict metastatic progression of good prognosis cancers is: - more accurate than the previous versions of biomarkers - Simpler & faster to perform, - Less expensive Thickness control of the cladding layer Rapid deposition Simple process Reduced cost No crucible (no contamination) Analysis of TMA breast & colorectal cancer samples with RT-QPCR and immunohistochemistry (cancer samples considered of good prognosis using classical markers – Gleason 1 to 4 for colon cancer and SBR 1 to 3 for breast cancer).